Metformin: a practical guide to optimising outcomes

Nathan DM , Buse JB , Davidson MB et al. Management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. Diabetologia 2006;49:1711-21.

National Institute for health and Clinical Excellence. Clinical Guideline G. Type 2 diabetes: the management type 2 diabetes (update) . NICE. London 2008. www.nice.org.uk (Accessed May 2008)

UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352:854-65.

Bailey CJ , Turner RC Metformin. N Engl J Med 1996; 334:574-9.

Wiernsperger NF 50 years later: is metformin a vascular drug with antidiabetic properties? Br J Diabetes Vasc Dis 2007;7:204-10.

Zhou G. , Myers R. , Li Y. et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-74.

Glucophage. Summary of Product Characteristics , 2004.

Glucophage SR Summary of Product Characteristics, 2006.

Feher MD , Al-Mrayat M. , Brake J. , Leong KS Tolerability of prolonged release metformin (Glucophage SR) in individuals intolerant to standard metformin - results from four UK centres. Br J Diabetes Vasc Dis 2007;7:22A5-8.

Krentz AJ , Bailey CJ Type 2 diabetes in practice (2nd edn). Royal Society of Medicine Press, London, 2005, 206pp.

Holstein A. , Stumvoll M. Contraindications can damage your health - is metformin a case in point? Diabetologia 2005;48:2454-9.

Douek IF , Allen SE , Ewings P. et al. Continuing metformin when starting insulin in patients with type 2 diabetes: a double-blind randomised placebo-controlled trial. Diabetic Med 2005; 22:634-40.

Salpeter S. , Greyber E. , Pasternak G. , Salpeter E. Risk of fatal and non-fatal lactic acidosis with metformin use in type 2 diabetes mellitus Cochrane Database Syst Rev CD002967.